62 related articles for article (PubMed ID: 32553555)
1. Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
Liu Y; Zeng H; Wang K; Li Y; Tian P; Li W
Lung Cancer; 2020 Aug; 146():355-357. PubMed ID: 32553555
[TBL] [Abstract][Full Text] [Related]
2. Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.
Inoue T; Kunimasa K; Tamiya M; Kawamura T; Minami T; Nishino K
Thorac Cancer; 2024 Apr; 15(11):929-933. PubMed ID: 38429896
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
4. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
[TBL] [Abstract][Full Text] [Related]
5. Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations.
Chimbangu CT; Ya Z; Xi L; Jiayue Z; Xiao M; Ying W; Xingxu Y; Liu X
Anticancer Drugs; 2024 Jan; 35(1):109-115. PubMed ID: 37578745
[TBL] [Abstract][Full Text] [Related]
6. A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening.
Lung J; Hung MS; Lin YC; Jiang YY; Fang YH; Lu MS; Hsieh CC; Wang CS; Kuan FC; Lu CH; Chen PT; Lin CM; Chou YL; Lin CK; Yang TM; Chen FF; Lin PY; Hsieh MJ; Tsai YH
Sci Rep; 2020 Oct; 10(1):16943. PubMed ID: 33037234
[TBL] [Abstract][Full Text] [Related]
7. Characterization of
Watanabe H; Inoue Y; Karayama M; Yazawa S; Mochizuka Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Shinmura K; Inui N; Suda T
JCO Precis Oncol; 2024 Apr; 8():e2300538. PubMed ID: 38662982
[TBL] [Abstract][Full Text] [Related]
8. Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.
Falkman L; Sundin A; Skogseid B; Botling J; Bernardo Y; Wallin G; Zhang L; Welin S; Lase I; Mollazadegan K; Crona J
Ups J Med Sci; 2024; 129():. PubMed ID: 38716076
[TBL] [Abstract][Full Text] [Related]
9. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
Tan X; Wu Z; Chen M
Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
[TBL] [Abstract][Full Text] [Related]
10. Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic
Huang Y; Zhang S; Hu X; Wang X; Zhao Y; Li Z
AME Case Rep; 2024; 8():38. PubMed ID: 38711893
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound-propelled liposome circumvention and siRNA silencing reverse BRAF mutation-arised cancer resistance to trametinib.
Chen J; Fang C; Chang C; Wang K; Jin H; Xu T; Hu J; Wu W; Shen E; Zhang K
Colloids Surf B Biointerfaces; 2024 Feb; 234():113710. PubMed ID: 38113749
[TBL] [Abstract][Full Text] [Related]
12. A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review.
Liu Y; Li M; Guo Y; Zhang Z; Du L; Zhang X; Wang Y; Zhang D; Xue L; Lei B; Su J; Zhang R; Chen J; Zhang X; Jia Q; Tian C
Pathol Res Pract; 2024 May; 259():155371. PubMed ID: 38820929
[TBL] [Abstract][Full Text] [Related]
13. Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
Ota T; Okabayashi A; Fukuoka M
Respirol Case Rep; 2021 Oct; 9(10):e0841. PubMed ID: 34484797
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
Zhou I; Plana D; Palmer AC
Clin Cancer Res; 2024 Feb; 30(4):786-792. PubMed ID: 38109210
[TBL] [Abstract][Full Text] [Related]
15. Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report.
Su PL; Lin CY; Chen YL; Chen WL; Lin CC; Su WC
JTO Clin Res Rep; 2021 Aug; 2(8):100202. PubMed ID: 34590045
[TBL] [Abstract][Full Text] [Related]
16. Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report.
Sposito M; Scaglione IM; Eccher S; Pasqualin L; Avancini A; Colato C; Rosina P; Simbolo M; Caliò A; Scarpa A; Milella M; Pilotto S; Belluomini L
JTO Clin Res Rep; 2023 Dec; 4(12):100597. PubMed ID: 38124787
[TBL] [Abstract][Full Text] [Related]
17. [Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK].
Messekher M; François H; Denis MG; Ferrer-Lopez P; Bost-Bezeaud F; Mazières J; Parrat E
Rev Mal Respir; 2024 May; ():. PubMed ID: 38796386
[TBL] [Abstract][Full Text] [Related]
18. Effective Treatment of Lung Adenocarcinoma With a Novel SLC44A1-BRAF Fusion Using Pembrolizumab Followed by Trametinib: A Case Report.
Yasui S; Honda T; Onishi I; Ikeda S; Miyazaki Y
Cureus; 2024 Feb; 16(2):e54739. PubMed ID: 38523924
[TBL] [Abstract][Full Text] [Related]
19. A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination.
Singh M; Cornwell S; Shaddaie A; Wachsmuth L; Ragupathi A; Salichos L; Nissel-Horowitz S; Roy R; Plummer M; Zhang D; Mehrotra B
Gynecol Oncol Rep; 2024 Aug; 54():101417. PubMed ID: 38808271
[TBL] [Abstract][Full Text] [Related]
20. Novel BRAF N581S mutation in mantle cell lymphoma.
Hariharan N; Bedi D; Choi MY; Wang HY; Heyman BM
EJHaem; 2024 Feb; 5(1):247-250. PubMed ID: 38406519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
